Pharmacopsychiatry, Table of Contents Pharmacopsychiatry 2015; 48(01): 37-39DOI: 10.1055/s-0034-1394368 Letter © Georg Thieme Verlag KG Stuttgart · New York Increased Platelet Count after Treatment with Venlafaxine or Mirtazapine in Depressed Patients W. Gronau 1 Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany , G. Paslakis 1 Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany , F. Lederbogen 1 Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany , B. Weber-Hamann 1 Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany 2 Kerckhoff Clinic, Bad Nauheim, Germany , M. Gilles 1 Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany , C. Schilling 1 Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany , M. Deuschle 1 Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany › Author Affiliations Recommend Article Abstract Buy Article Key words Key wordsplatelet count - platelet volume - antidepressant - mirtazapine - venlafaxine - major depressive disorder Full Text References References 1 WHO. The top 10 causes of death. (accessed on 22nd June 2014) http://www.who.int/mediacentre/factsheets/fs310/en/index2.html 2 Vitthal K, Jayaraj S, Deepak K et al. Mean platelet volume and other platelet volume indices in patients with stable coronary artery disease and acute myocardial infarction: A case control study. J Cardiovasc Dis Res 2012; 3: 272-275 3 Endler G, Klimesch A, Sunder-Plassmann H et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404 4 Maden O, Kacmaz F, Selcuk H et al. Relationship of admission hematological indexes with myocardial reperfusion abnormalities in acute ST segment elevation myocardial infarction patients treated with primary percutaneous coronary interventions. Can J Cardiol 2009; 25: e164-e168 5 Halaris A. Inflammation, heart disease, and depression. Curr Psychiatry Rep 2013; 15: 400 6 Seidel A, Arolt V, Hunstiger M et al. Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 1996; 94: 198-204 7 Canan F, Dikici S, Kutlucan A et al. Association of mean platelet volume with DSM-IV major depression in a large community-based population: the MELEN study. J Psychiatr Res 2012; 46: 298-302 8 Lopez-Vilchez I, Serra-Millas M, Navarro V et al. Prothrombotic platelet phenotype in major depression: downregulation by antidepressant treatment. Affect Disord 2014; 159: 39-45 9 Hausberg M, Hillebrand U, Kisters K. Addressing sympathetic overactivity in major depressive disorder. J Hypertens 2007; 25: 2004-2005 10 Ragolsky M, Shimon H, Shalev H et al. Suicidal thoughts are associated with platelet counts in adolescent inpatients. J Child Adolesc Psychopharmacol 2013; 23: 49-53 11 Siddiqui R, Gawande S, Shende T et al. SSRI-induced coagulopathy: is it reality?. Ther Adv Psychopharmacol 2011; 1: 169-174 12 Song HR, Jung YE, Wang HR et al. Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients. Psych Clin Neurosci 2012; 66: 457-459 13 Krivy J, Wiener J. Sertraline and platelet counts in idiopathic thrombocytopenia purpura. Lancet 1995; 345: 132 14 Lederbogen F, Horer E, Hellweg R et al. Platelet counts in depressed patients treated with amitriptyline or paroxetine. Eur Psychiatry 2003; 18: 89-91 15 Van Kempen GMJ, Zitman FG, Linssen ACG et al. Biochemical measures in patients with a somatoform pain disorder, before, during and after treatment with amitriptyline with or without flupentixol. Pain 1991; 47: 25-30 16 Ariyo AA, Haan M, Tangen CM et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation 2000; 102: 1773-1779 17 Ataoglu A, Canan F. Mean platelet volume in patients with major depression: effect of escitalopram treatment. J Clin Psychopharmacol 2009; 29: 368-371 18 Serebruany VL, Glassman AH, Malinin AI et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-944 19 Hoirisch-Clapausch S, Nardi AE, Gris JC et al. Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?. Thromb Res 2014; 134: 11-16 20 Schins A, Hamulyak K, Scharpe S et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sci 2004; 76: 637-650 21 Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81 22 Tharmapathy P, Selheim F, Odegaard K et al. Venlafaxine treatment stimulates blood platelet activity. J Clin Psychopharmacol 2000; 20: 589-590 23 Hallbäck I, Hägg S, Eriksson AC et al. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacol Rep 2012; 64: 979-983 24 Sarma A, Horne 3rd MK. Venlafaxine-induced ecchymoses and impaired platelet aggregation. Eur J Haematol 2006; 77: 533-537 25 Maes M, Ruckoanich P, Chang YS et al. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 769-783
